What were the main drivers of the 10% sales increase in the first quarter of 2004?

The 10% increase in net sales to $5.2 billion was primarily driven by a 6% increase in sales volume and a favorable 5% impact from foreign exchange rate fluctuations. Price changes had a minor negative impact of 1%.

How did the sale of the Mead Johnson Adult Nutritional business impact the company's earnings?

The sale of the Mead Johnson Adult Nutritional business resulted in a pre-tax gain of $295 million, which significantly contributed to the reported net earnings increase of 22% for the quarter.

What is the company's outlook regarding upcoming product exclusivity losses and their impact?

Bristol-Myers Squibb anticipates significant exclusivity losses in the coming years, estimating declines in net sales between $1.2 to $1.3 billion in 2004 from products losing exclusivity in 2003 or 2004. These losses are expected to continue and are projected to impact future sales and margins, particularly for established, higher-margin products.

What is the company's stance on its significant legal proceedings?

The company acknowledges numerous significant pending lawsuits, claims, proceedings, and investigations. While it records accruals for probable and estimable losses, management states that it is not currently possible to reasonably assess the final outcome of these matters. They believe the aggregate impact, beyond current reserves, is reasonably likely to be material to future results of operations, cash flows, financial condition, and liquidity.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2004

Summary

Bristol-Myers Squibb Company (BMY) reported strong financial results for the first quarter of 2004. Net sales increased by 10% to $5.2 billion, driven by a 6% volume increase and a favorable 5% impact from foreign exchange fluctuations. This growth was seen across both U.S. and international markets, with international sales showing a significant 18% increase. Net earnings saw a substantial rise of 22% to $964 million, translating to earnings per share of $0.50 basic and $0.49 diluted, up from $0.41 in the prior year. This improved profitability was bolstered by a significant $295 million pre-tax gain from the divestiture of the Mead Johnson Adult Nutritional business. The company also demonstrated continued commitment to innovation, increasing research and development spending by 23% to $583 million, with a particular focus on its pharmaceutical pipeline.

Key Highlights

1Net sales increased by 10% year-over-year to $5.2 billion, driven by volume and favorable foreign exchange rates.
2Net earnings rose 22% to $964 million, with earnings per share increasing to $0.50 (basic) and $0.49 (diluted).
3A gain of $295 million was recognized from the sale of the Mead Johnson Adult Nutritional business.
4Research and development expenses increased by 23% to $583 million, reflecting investment in pipeline development.
5Strong performance was noted in key product areas like PLAVIX, ABILIFY, and ERBITUX, despite some challenges from generic competition on older products.
6The company's cash, cash equivalents, and marketable securities stood at $6.6 billion, providing robust liquidity.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2004

Summary

Key Highlights

Frequently Asked Questions